Jacquet J M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi J F
Laboratoire Universitaire de Thérapeutique, Faculté de Médecine, Montpellier-Nîmes, France.
Cancer Chemother Pharmacol. 1990;27(3):219-25. doi: 10.1007/BF00685716.
Doxorubicin was given by short i.v. infusion (dose range 25-72 mg/m2) to 18 patients who underwent three to seven successive courses of chemotherapy (total, 57 courses). Plasma levels of doxorubicin and its major metabolite doxorubicinol were determined by high-performance liquid chromatography over a 48-h period after the infusion. Pharmacokinetic parameters for the parent drug and its metabolite were calculated for each course of treatment. The results show considerable inter- and intraindividual variations for most parameters. The coefficients of variation (CV) ranged from 37% to 93% (inter-individual) and from 6% to 59% (intra-individual). Nevertheless, we observed a good stability over successive courses for terminal half-life in six patients (CV, 6%-25%) and for clearance and AUC in four subjects (CV, 10%-22%). The ratio of the AUCs for doxorubicinol: doxorubicin averaged 0.514. The pharmacokinetic pattern of doxorubicinol was biphasic in plasma of the majority of patients. We propose a model for curve-fitting of these metabolite plasma concentrations that is based on two successive releases of the compound in the plasma compartment, separated by a lag time.
对18例患者进行了三至七个疗程的化疗(共57个疗程),通过短时间静脉输注给予阿霉素(剂量范围为25 - 72mg/m²)。在输注后的48小时内,采用高效液相色谱法测定血浆中阿霉素及其主要代谢产物阿霉素醇的水平。计算每个疗程中母体药物及其代谢产物的药代动力学参数。结果显示,大多数参数存在显著的个体间和个体内差异。变异系数(CV)范围为37%至93%(个体间)和6%至59%(个体内)。然而,我们观察到6例患者的终末半衰期(CV为6% - 25%)以及4例受试者的清除率和AUC在连续疗程中具有良好的稳定性。阿霉素醇与阿霉素的AUC比值平均为0.514。在大多数患者的血浆中,阿霉素醇的药代动力学模式呈双相。我们提出了一种基于该化合物在血浆隔室中两次连续释放且有滞后时间的代谢物血浆浓度曲线拟合模型。